A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer

[1] Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424

[2] Brewster AM(2008)Residual risk of breast cancer recurrence 5 years after adjuvant therapy J Natl Cancer Inst 100 1179-1183

[3] Hortobagyi GN(2018)Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer Ann Oncol 29 1541-1547

[4] Hortobagyi G(2021)LBA17 overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET)±ribociclib (RIB) Ann Oncol 32 S1290-S1291

[5] Towle MJ(2001)In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B Can Res 61 1013-1021

[6] Kuznetsov G(2004)Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389 Can Res 64 5760-5766

[7] Jordan MA(2005)The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth Mol Cancer Ther 4 1086-1095

[8] Smith JA(2010)Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability Biochemistry 49 1331-1337

[9] Okouneva T(2008)Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase Mol Cancer Ther 7 2003-2011

[10] Kawano S(2016)Antimitotic and non-mitotic effects of eribulin mesilate in soft tissue sarcoma Anticancer Res 36 1553-1561

[1] Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424

[2] Brewster AM(2008)Residual risk of breast cancer recurrence 5 years after adjuvant therapy J Natl Cancer Inst 100 1179-1183

[3] Hortobagyi GN(2018)Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer Ann Oncol 29 1541-1547

[4] Hortobagyi G(2021)LBA17 overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET)±ribociclib (RIB) Ann Oncol 32 S1290-S1291

[5] Towle MJ(2001)In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B Can Res 61 1013-1021

[6] Kuznetsov G(2004)Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389 Can Res 64 5760-5766

[7] Jordan MA(2005)The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth Mol Cancer Ther 4 1086-1095

[8] Smith JA(2010)Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability Biochemistry 49 1331-1337

[9] Okouneva T(2008)Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase Mol Cancer Ther 7 2003-2011

[10] Kawano S(2016)Antimitotic and non-mitotic effects of eribulin mesilate in soft tissue sarcoma Anticancer Res 36 1553-1561